The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that clinically relevant doses of buspirone will occupy the D3 receptor.
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Basic Science
- Masking: None (Open Label)
- Study Primary Completion Date: June 2014
Buspirone is used for anxiety disorder treatment, a therapeutic effect that has been thought to be mediated through its partial agonist properties at the serotonin receptor. However, since one PET study in humans has shown low occupancy of the serotonin by buspirone in clinical doses and since the DRD3 has been recently implicated in anxiety, some therapeutic effects of buspirone may be mediated through the DRD3. In human clinical studies, promising effects of buspirone have been reported for treatment of substance dependence, including tobacco, marijuana, and opiates, and clinical studies in cocaine dependent subjects are underway. However, it is unclear if buspirone is producing those effects through the DRD3 and no human study has incorporated a PET imaging component to investigate this question; it remains unclear whether buspirone significantly occupies the DRD3 at therapeutic doses in humans.
- Drug: Buspirone
- The buspirone will be given once as a tablet and encapsulated for blinding.
- Drug: Placebo
- Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
Arms, Groups and Cohorts
- Experimental: Buspirone 120 mg
- Buspirone 120 mg (encapsulated).
- Experimental: Buspirone 60 mg
- Buspirone 60 mg (encapsulated)
- Placebo Comparator: Placebo
- Placebo (encapsulated)
- Experimental: Buspirone 30 mg
- Buspirone 30 mg (encapsulated).
Clinical Trial Outcome Measures
- Dose-response occupancy of buspirone at DRD3
- Time Frame: few months
- [11C]-(+)-PHNO binding potential at three doses of buspirone and placebo.
Participating in This Clinical Trial
- 19 years or older
- Medical condition including cardiovascular, renal, hepatic or cerebrovascular diseases
- History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor, – Present or past psychiatric condition including mood, anxiety, psychotic disorders and substance abuse and/or dependence.
- Condition that precludes use of buspirone or that will interfere with participation in the present study (such as hypersensitive to buspirone hydrochloride).
- Pregnancy or breastfeeding.
- Presence of metal objects in the body or implanted electronic devices, that preclude safe MR scanning.
- Current use or use during the previous month of medication that may affect the CNS, including monoamine oxidase inhibitor (MAOI) or positive during drug screening for drugs of abuse or any medication that could increase the risk of buspirone administration.
- Exposure to radiation in the last 12 month exceeding permissible limit for subjects participating in research.
Gender Eligibility: All
Minimum Age: 19 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Centre for Addiction and Mental Health
- Provider of Information About this Clinical Study
- Principal Investigator: Bernard Le Foll, PI – Centre for Addiction and Mental Health
- Overall Official(s)
- Isabelle Boileau, PhD, Principal Investigator, Center for Addiction and Mental Health
- Bernard Le Foll, MD, PhD, Principal Investigator, Center for Addiction and Mental Health
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.